Technical Analysis for GRCL - Gracell Biotechnologies Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | N/A |
| Historical GRCL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -2.44% | |
| Hot IPO Pullback | Bullish Swing Setup | -2.44% | |
| Hot IPO Pullback | Bullish Swing Setup | -4.34% | |
| Outside Day | Range Expansion | -4.34% | |
| New 52 Week Closing High | Bullish | -5.77% | |
| Inside Day | Range Contraction | -5.77% | |
| New 52 Week Closing Low | Bearish | -3.23% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Down 3% | 2 days ago | |
| 60 Minute Opening Range Breakdown | 2 days ago | |
| Down 2 % | 2 days ago | |
| Reversed from Down | 2 days ago | |
| Gap Down Closed | 2 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Solid Tumors Immune System Health Sciences Lymphoma Cancer Immunotherapy Gene Therapy Chimeric Antigen Receptor T Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Solid Tumors Immune System Health Sciences Lymphoma Cancer Immunotherapy Gene Therapy Chimeric Antigen Receptor T Cell
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.88 |
| 52 Week Low | 22.3 |
| Average Volume | 549,743 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 0.00 |
| Average True Range | 0.00 |
| ADX | 0.0 |
| +DI | 0.00 |
| -DI | 0.00 |
| Chandelier Exit (Long, 3 ATRs ) | N/A |
| Chandelier Exit (Short, 3 ATRs ) | N/A |
| Upper Bollinger Band | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.71 | ||||
| Resistance 3 (R3) | 25.81 | 25.35 | 25.43 | ||
| Resistance 2 (R2) | 25.35 | 24.91 | 25.30 | 25.33 | |
| Resistance 1 (R1) | 24.67 | 24.64 | 24.44 | 24.57 | 25.23 |
| Pivot Point | 24.21 | 24.21 | 24.09 | 24.16 | 24.21 |
| Support 1 (S1) | 23.53 | 23.77 | 23.30 | 23.43 | 22.77 |
| Support 2 (S2) | 23.07 | 23.50 | 23.02 | 22.67 | |
| Support 3 (S3) | 22.39 | 23.07 | 22.58 | ||
| Support 4 (S4) | 22.29 |
